X4 Pharmaceuticals, Inc.

Background:

X4 Pharmaceuticals, Inc. is focused on delivering innovative treatments to patients with rare diseases of the immune system. The company achieved its first-ever approval in April 2024 for a product indicated in patients with WHIM syndrome – a relatively unknown, ultra rare immunodeficiency affecting approximately 1,000 people in the U.S.

With the approval of its first medicine, a selective CXCR4 antagonist that has the potential to address multiple other rare diseases, this moment served as a critical catalyst for the future of X4, as well as for the rare immunodeficiency community.

Media strategy and outcomes:

Breaking through to media amid a competitive and rapid news cycle for a potential drug approval, and in a rare indication, required significant advance planning. Ten Bridge worked quickly over the course of several weeks to educate media ahead of the decision date milestone to ensure its significance was put into context for reporters. This way, they would be compelled to write feature stories if an approval came. The combination of the pre-decision media engagement and the robust approach to media outreach at the time of approval led to a wealth of day-of coverage across local, biotech and HCP-focused trade media.

Strategic partner as an extension of the X4 team:

Ten Bridge provided end-to-end support on the planning and execution of corporate communication strategy for the U.S. FDA approval of X4’s product. Working as an extension of the X4 team, we contributed to the strategy development, scenario planning and implementation of communication across various stakeholders, both internal and external, to maximize the impact of the news to X4’s key audiences – including investors, members of the media, healthcare providers and the patient community.